Literature DB >> 765518

Trimethoprim-sulfamethoxazole therapy for shigellosis.

J D Nelson, H Kusmiesz, L H Jackson, E Woodman.   

Abstract

Twenty-eight infants and children hospitalized for severe shigellosis were treated orally either with ampicillin trihydrate (100 mg/kg/day administered in divided doses every six hours) or with trimethoprim-sulfamethoxazole (trimethoprim, 10 mg; sulfamethoxazole, 50 mg/kg/day in divided doses every 12 hours) for five days. Four patients with ampicillin-resistant shigellae continued to have diarrhea and positive stool cultures during therapy. Patients with susceptible shigellae treated with ampicillin and all patients treated with trimethoprim-sulfamethoxazole responsed promptly and comparably within an average of 1.6 and 1.7 days, respectively, until stool cultures were negative, and 3.1 and 2.9 days, respectively, until diarrhea stopped. Patients with ampicillin-resistant shigellae responded to treatment with trimethoprim-sulfamethoxazole. It is concluded that trimethoprim-sulfamethoxazole is the best currently available drug for treatment of shigellosis in areas where multiple antibiotic resistance of shigellae is common.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 765518

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  23 in total

1.  Therapeutic methods for diarrhea in children.

Authors:  S K Bhattacharya
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

2.  Antibiotic resistance among common bacterial enteric pathogens isolated from stool.

Authors:  B V Navaneeth; N Suganthi; M R Belwadi
Journal:  Indian J Pediatr       Date:  2001-07       Impact factor: 1.967

3.  Retrospective analysis of the first clonal outbreak of nalidixic acid-resistant Shigella sonnei shigellosis in Israel.

Authors:  D Dagan; N Orr; M Yavzori; Y Yuhas; D Meron; S Ashkenazi; D Cohen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-12-10       Impact factor: 3.267

4.  Trimethoprim- sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions.

Authors:  M A Kielhofner
Journal:  Tex Heart Inst J       Date:  1990

5.  High prevalence of antimicrobial resistance among Shigella isolates in the United States tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002.

Authors:  Sumathi Sivapalasingam; Jennifer M Nelson; Kevin Joyce; Mike Hoekstra; Frederick J Angulo; Eric D Mintz
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  Shigella flexneri Type 2 Infection in Captive Nonhuman Primates.

Authors:  R Higgins; R Sauvageau; P Bonin
Journal:  Can Vet J       Date:  1985-12       Impact factor: 1.008

7.  Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study.

Authors:  H L DuPont; C D Ericsson; J J Mathewson; M W DuPont
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

8.  Isolation and development of bioluminescent reporter phages for bacterial dysentery.

Authors:  D A Schofield; D J Wray; I J Molineux
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-25       Impact factor: 3.267

9.  Common bacterial infections in infancy and childhood. 6. Enteric infections.

Authors:  M I Marks
Journal:  Drugs       Date:  1978-09       Impact factor: 9.546

10.  Sulfamethoxazole- trimethoprim versus ampicillin in treatment of acute invasive diarrhea in adults.

Authors:  F A Barada; R L Guerrant
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.